Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01502410 · OUTCOME

Change in VEGF and VEGFR-2

Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer · Source last updated 2018-06-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
picograms/ml
Interval / dispersion
Full Range
Time frame
Prior to the administration of sorafenib (baseline) and day 15 of protocol therapy

What was measured

Serum VEGF and VEGF receptor 2 Concentration is evaluated at baseline and at day 15 of protocol therapy in picograms/ml.

Analysis population: Change in VEGF and VEGFR-2 are the responses of the patient's organs to the drug. As such, these measures are unrelated to the particular disease with which the patient was diagnosed, and were combined for analysis.

Groups in this outcome

Rhabdomyosarcoma and Wilms Tumor

Not reported

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Rhabdomyosarcoma and Wilms Tumor9

Reported measurements

VEGF Baseline
Values in picograms/ml · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Rhabdomyosarcoma and Wilms Tumor155.75Not reported28.01452.22Not reported
VEGF Day 15
Values in picograms/ml · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Rhabdomyosarcoma and Wilms Tumor209.92Not reported70.10470.38Not reported
VEGF-R2 Baseline
Values in picograms/ml · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Rhabdomyosarcoma and Wilms Tumor9594.04Not reported651.815576.39Not reported
VEG-R2 Day 15
Values in picograms/ml · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Rhabdomyosarcoma and Wilms Tumor7948.48Not reported5569.7311637.18Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        28.01
        upper Limit
        452.22
        value
        155.75
    title
    VEGF Baseline
  2. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        70.10
        upper Limit
        470.38
        value
        209.92
    title
    VEGF Day 15
  3. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        651.8
        upper Limit
        15576.39
        value
        9594.04
    title
    VEGF-R2 Baseline
  4. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        5569.73
        upper Limit
        11637.18
        value
        7948.48
    title
    VEG-R2 Day 15
denoms
  1. counts
    1. group Id
      OG000
      value
      9
    units
    Participants
description
Serum VEGF and VEGF receptor 2 Concentration is evaluated at baseline and at day 15 of protocol therapy in picograms/ml.
dispersion Type
Full Range
groups
  1. id
    OG000
    title
    Rhabdomyosarcoma and Wilms Tumor
param Type
MEAN
population Description
Change in VEGF and VEGFR-2 are the responses of the patient's organs to the drug. As such, these measures are unrelated to the particular disease with which the patient was diagnosed, and were combined for analysis.
reporting Status
POSTED
time Frame
Prior to the administration of sorafenib (baseline) and day 15 of protocol therapy
title
Change in VEGF and VEGFR-2
type
SECONDARY
unit Of Measure
picograms/ml

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice